Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease

Post-marketing Surveillance of Berodual® Metered-dose Inhaler in the Treatment of Chronic Obstructive Respiratory Tract Disease

NCT02231437 ·Status: COMPLETED

Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique.

NCT00267917 ·Status: COMPLETED ·Phase: PHASE4

Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00153075 ·Status: COMPLETED ·Phase: PHASE4

Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease

NCT02231424 ·Status: COMPLETED

Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease

NCT01019694 ·Status: COMPLETED ·Phase: PHASE3

Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease

NCT02232594 ·Status: COMPLETED

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BEA 2180 BR in Healthy Male Volunteers

NCT02254122 ·Status: COMPLETED ·Phase: PHASE1

Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease

NCT02177253 ·Status: COMPLETED ·Phase: PHASE3

Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD Patients

NCT02242279 ·Status: COMPLETED ·Phase: PHASE2

12 / 48 wk Pivotal PFT vs PBO in COPD II

NCT00782509 ·Status: COMPLETED ·Phase: PHASE3

Dose Finding Study in COPD

NCT00122434 ·Status: COMPLETED ·Phase: PHASE2

12 / 48 Week Pivotal PFT vs PBO in COPD I

NCT00782210 ·Status: COMPLETED ·Phase: PHASE3

An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.

NCT00528996 ·Status: COMPLETED ·Phase: PHASE2

Study to Assess the Safety of Ipratropium Bromide, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT02236182 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy of Two Different Doses of Ipratropium Bromide Versus ATROVENT® Inhalation Aerosol in Adults With Chronic Obstructive Pulmonary Disease

NCT02177344 ·Status: COMPLETED ·Phase: PHASE3

BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD

NCT00846768 ·Status: COMPLETED ·Phase: PHASE2

Acute Bronchodilator Effect of Inhaled Albuterol Sulfate and Ipratropium Bromide in Patients With Stable COPD

NCT03480997 ·Status: COMPLETED ·Phase: PHASE1

Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.

NCT00452400 ·Status: COMPLETED ·Phase: PHASE2

Re-usable Respimat® Soft MistTM Inhaler Study

NCT04011735 ·Status: COMPLETED

A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale

NCT04223843 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00720499 ·Status: COMPLETED ·Phase: PHASE2

Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

NCT00696020 ·Status: COMPLETED ·Phase: PHASE2

12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

NCT00239473 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I

NCT00793624 ·Status: COMPLETED ·Phase: PHASE3

The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease

NCT02845752 ·Status: COMPLETED ·Phase: PHASE4